DaVita (DVA) Stock Price

DaVita Price

NYSE·CLOSED
180.67USD-7.33 (-3.98 %)
Market closed

Over the last 19 years DaVita grew revenue by 5.6% annually, reaching 13.64 B USD. Earnings per share have grown at 10.0% per year over the last 19 years. For DaVita, the net margin of 5.5% is down versus 8.4% a few years ago. The consensus 12-month price target for DaVita is 135.66 USD, about 24.9% below where the stock trades today. Of 17 analysts, 1 rate the stock a buy — an overall Hold consensus. The stock trades about 74% above its 52-week low.

DaVita stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of DaVita over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how DaVita stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing DaVita's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

DaVita Stock Price History
DateDaVita Price
8/6/2026180.67 USD
8/5/2026188.00 USD
8/4/2026233.12 USD
8/3/2026233.68 USD
7/31/2026240.09 USD
7/30/2026238.86 USD
7/29/2026241.69 USD
7/27/2026237.85 USD
7/23/2026234.27 USD
7/22/2026232.08 USD
7/21/2026237.28 USD
7/20/2026234.10 USD
7/17/2026236.97 USD
7/16/2026234.01 USD
7/15/2026231.61 USD
7/14/2026232.41 USD
7/13/2026235.91 USD
7/10/2026232.80 USD
7/9/2026229.48 USD
7/8/2026233.13 USD
7/7/2026234.31 USD
7/6/2026236.77 USD
7/2/2026234.91 USD
7/1/2026228.03 USD
6/30/2026222.48 USD
6/29/2026216.43 USD
6/26/2026217.04 USD
6/25/2026213.36 USD
6/24/2026213.04 USD
6/23/2026210.93 USD
6/22/2026213.55 USD
6/18/2026208.57 USD
6/17/2026211.04 USD
6/16/2026207.96 USD
6/15/2026209.37 USD
6/12/2026210.74 USD
6/11/2026201.59 USD
6/10/2026197.54 USD
6/9/2026198.19 USD
6/8/2026192.08 USD
6/5/2026194.98 USD
6/4/2026196.82 USD
6/3/2026192.18 USD
6/2/2026189.74 USD
6/1/2026190.71 USD
5/29/2026196.60 USD
5/28/2026197.71 USD
5/27/2026195.74 USD
5/26/2026198.38 USD
5/22/2026198.32 USD
5/21/2026195.93 USD
5/20/2026197.07 USD
5/19/2026194.61 USD
5/18/2026199.52 USD
5/15/2026199.74 USD
5/14/2026192.58 USD
5/13/2026198.10 USD
5/12/2026200.54 USD
5/11/2026198.93 USD
5/8/2026198.65 USD
5/7/2026196.26 USD
5/6/2026193.88 USD
5/5/2026157.04 USD
5/4/2026154.08 USD
5/1/2026151.65 USD
4/30/2026155.14 USD
4/29/2026151.99 USD
4/28/2026150.07 USD
4/27/2026150.05 USD
4/24/2026151.85 USD
4/23/2026155.03 USD
4/22/2026152.42 USD
4/21/2026149.90 USD
4/20/2026149.33 USD
4/17/2026147.91 USD
4/16/2026148.13 USD
4/15/2026144.57 USD
4/14/2026149.45 USD
4/13/2026151.56 USD
4/10/2026150.05 USD
4/9/2026150.68 USD
4/8/2026148.44 USD
4/7/2026149.70 USD
4/6/2026150.12 USD
4/2/2026145.58 USD
4/1/2026150.34 USD
3/31/2026153.69 USD
3/30/2026152.37 USD
3/27/2026154.43 USD
3/26/2026156.76 USD
3/25/2026155.11 USD
3/24/2026153.28 USD
3/23/2026152.21 USD
3/20/2026149.31 USD
3/19/2026149.76 USD
3/18/2026149.76 USD
3/17/2026149.98 USD
3/16/2026148.22 USD
3/13/2026150.72 USD
3/12/2026153.06 USD
3/11/2026154.81 USD
3/10/2026151.55 USD
3/9/2026152.56 USD
3/6/2026150.76 USD
3/5/2026149.94 USD
3/4/2026154.79 USD
3/3/2026152.27 USD
3/2/2026153.98 USD
2/27/2026156.30 USD
2/26/2026152.54 USD
2/25/2026149.51 USD
2/24/2026150.91 USD
2/23/2026151.28 USD
2/20/2026150.73 USD
2/19/2026147.34 USD
2/18/2026147.75 USD
2/17/2026150.41 USD
2/13/2026148.95 USD
2/12/2026149.97 USD
2/11/2026144.27 USD
2/10/2026139.28 USD
2/9/2026137.64 USD
2/6/2026140.90 USD
2/5/2026149.90 USD
2/4/2026142.06 USD
2/3/2026134.73 USD
2/2/2026126.51 USD
1/30/2026108.75 USD
1/29/2026107.24 USD
1/28/2026105.88 USD
1/27/2026105.61 USD
1/26/2026107.51 USD
1/23/2026108.12 USD
1/22/2026109.17 USD
1/21/2026106.30 USD
1/20/2026103.93 USD
1/16/2026104.74 USD
1/15/2026105.84 USD
1/14/2026103.87 USD
1/13/2026104.47 USD
1/12/2026111.01 USD
1/9/2026111.45 USD
1/8/2026112.59 USD
1/7/2026111.01 USD
1/6/2026114.72 USD
1/5/2026113.94 USD
1/2/2026114.51 USD
12/31/2025113.61 USD
12/30/2025113.82 USD
12/29/2025113.50 USD
12/26/2025113.98 USD
12/24/2025114.41 USD
12/23/2025114.72 USD
12/22/2025116.51 USD
12/19/2025115.20 USD
12/18/2025116.15 USD
12/17/2025118.42 USD
12/16/2025117.94 USD
12/15/2025120.05 USD
12/12/2025121.35 USD
12/11/2025120.33 USD
12/10/2025118.68 USD
12/9/2025116.67 USD
12/8/2025117.05 USD
12/5/2025117.39 USD
12/4/2025117.28 USD
12/3/2025118.25 USD
12/2/2025119.18 USD
12/1/2025119.24 USD
11/28/2025119.68 USD
11/26/2025120.10 USD
11/25/2025121.37 USD
11/24/2025119.49 USD
11/21/2025120.25 USD
11/20/2025115.35 USD
11/19/2025115.20 USD
11/18/2025116.56 USD
11/17/2025117.27 USD
11/14/2025121.55 USD
11/13/2025123.05 USD
11/12/2025123.60 USD
11/11/2025122.27 USD
11/10/2025120.17 USD
11/7/2025123.69 USD
11/6/2025121.53 USD
11/5/2025121.16 USD
11/4/2025119.97 USD
11/3/2025119.05 USD
10/31/2025119.02 USD
10/30/2025118.75 USD
10/29/2025123.91 USD
10/28/2025129.61 USD
10/27/2025129.55 USD
10/24/2025129.17 USD
10/23/2025128.02 USD
10/22/2025129.08 USD
10/21/2025128.41 USD
10/20/2025128.05 USD
10/17/2025125.89 USD
10/16/2025125.25 USD
10/15/2025126.00 USD
10/14/2025126.62 USD
10/13/2025123.91 USD
10/10/2025123.11 USD
10/9/2025126.38 USD
10/8/2025127.89 USD
10/7/2025131.04 USD
10/6/2025128.14 USD
10/3/2025131.41 USD
10/2/2025132.10 USD
10/1/2025132.87 USD
9/30/2025132.87 USD
9/29/2025130.59 USD
9/28/2025130.59 USD
9/25/2025130.80 USD
9/24/2025130.27 USD
9/23/2025132.83 USD
9/22/2025131.15 USD
9/19/2025130.17 USD
9/18/2025130.23 USD
9/17/2025128.00 USD
9/16/2025130.11 USD
9/15/2025130.95 USD
9/12/2025133.17 USD
9/11/2025133.24 USD
9/10/2025132.26 USD
9/9/2025136.71 USD
9/8/2025134.51 USD
9/5/2025137.96 USD
9/4/2025135.56 USD
9/3/2025135.97 USD
9/2/2025136.95 USD
8/29/2025137.25 USD
8/28/2025136.03 USD
8/27/2025137.56 USD
8/26/2025138.68 USD
8/25/2025137.33 USD
8/22/2025140.27 USD
8/21/2025137.31 USD
8/20/2025137.42 USD
8/19/2025136.68 USD
8/18/2025133.25 USD
8/15/2025136.10 USD
8/14/2025134.39 USD
8/13/2025134.69 USD
8/12/2025132.08 USD
8/11/2025129.05 USD
Access this data via the Eulerpool API

DaVita Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
11.61 B USD
1.32 B USD
560.40 M USD
Jan 1, 2023
12.14 B USD
1.60 B USD
691.54 M USD
Jan 1, 2024
12.82 B USD
2.09 B USD
936.34 M USD
Jan 1, 2025
13.64 B USD
2.01 B USD
746.80 M USD
Jan 1, 2026 (e)
14.09 B USD
1.96 B USD
1.13 B USD
Jan 1, 2027 (e)
14.52 B USD
2.02 B USD
1.32 B USD
Jan 1, 2028 (e)
14.60 B USD
2.03 B USD
1.45 B USD
Jan 1, 2029 (e)
15.89 B USD
2.21 B USD
1.37 B USD

DaVita Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 2:57 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
12.8013.7814.7510.8811.4011.3911.5511.6211.6112.1412.8213.6414.0914.5214.6015.89
8.767.717.00-26.244.85-0.141.420.59-0.084.575.566.463.303.000.578.86
28.7222.6822.2129.7528.1430.5030.8331.3829.2931.4732.9127.0027.0027.0027.0027.00
3.683.133.283.243.213.473.563.653.403.824.223.683.813.923.944.29
1.821.142.031.811.531.641.691.801.321.602.092.011.962.022.032.21
14.198.2413.7616.6613.3714.4314.6715.4711.4013.2016.3114.7313.9213.9213.9313.92
0.720.270.880.660.160.810.770.980.560.690.940.751.131.321.451.37
14.22-62.79226.77-24.57-76.02409.43-4.5726.52-42.7423.3935.46-20.3051.3416.4710.57-5.50
217.62208.76196.74184.83166.48130.50115.96104.8491.9192.7885.8088.1088.1088.1088.1088.10
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales DaVita generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue DaVita retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare DaVita's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares DaVita has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against DaVita's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

DaVita stock margins

The DaVita margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DaVita. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DaVita.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
31.38 %
15.47 %
8.42 %
Jan 1, 2022
29.29 %
11.40 %
4.83 %
Jan 1, 2023
31.47 %
13.20 %
5.70 %
Jan 1, 2024
32.91 %
16.31 %
7.31 %
Jan 1, 2025
27.00 %
14.74 %
5.47 %
Jan 1, 2026 (e)
27.00 %
13.93 %
8.01 %
Jan 1, 2027 (e)
27.00 %
13.93 %
9.06 %
Jan 1, 2028 (e)
27.00 %
13.93 %
9.96 %

DaVita Stock Revenue, EBIT, Earnings per Share

The DaVita earnings per share therefore indicates how much revenue DaVita has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
110.82 USD
17.14 USD
9.33 USD
Jan 1, 2022
126.32 USD
14.40 USD
6.10 USD
Jan 1, 2023
130.85 USD
17.27 USD
7.45 USD
Jan 1, 2024
149.37 USD
24.37 USD
10.91 USD
Jan 1, 2025
154.86 USD
22.82 USD
8.48 USD
Jan 1, 2026 (e)
185.73 USD
22.28 USD
14.88 USD
Jan 1, 2027 (e)
191.30 USD
22.95 USD
17.33 USD
Jan 1, 2028 (e)
192.38 USD
23.08 USD
19.16 USD

DaVita business model & stock analysis

DaVita Inc. is a company headquartered in Denver, Colorado, specializing in the provision and management of outpatient dialysis treatments (renal replacement therapy) and related services. The company was founded in 1999 and has since experienced impressive growth, with a presence in over ten countries worldwide. The history of DaVita traces back to the origin of its business model: outpatient dialysis treatment. This is a form of renal replacement therapy where patients can be treated outside of the hospital, in a dedicated center or even in their own homes. This type of dialysis is less intimidating compared to inpatient treatment in a hospital and can be much more flexible in terms of scheduling. DaVita took this idea and brought it to the market in the US and other countries, where it has proven to be extremely successful. Nowadays, DaVita operates in three main business segments. The first is the patient care segment, which focuses on providing dialysis treatments and related services. Here, DaVita offers outpatient dialysis centers where patients can receive regular treatment. Another important aspect of this segment is patient and family education, integrating them into the treatment process and helping them lead as normal a life as possible. The second core area is the pharmaceutical supply business. DaVita has an extensive network of facilities and suppliers, as well as its own pharmacies where the necessary medications for dialysis patients are manufactured and stored. DaVita also handles billing with insurance and other payment entities to ensure seamless patient care. The third core area of DaVita is the international supply company. Here, DaVita offers its services in over ten countries worldwide, including Mexico, Colombia, Brazil, Saudi Arabia, and Canada. DaVita has steadily expanded its international business in recent years and aims to have a presence in even more countries in the future. But DaVita does not limit itself to these three core areas. The company is also known for its innovative research and development efforts aimed at improving the treatment of kidney disease and developing new technologies. Products offered by DaVita include innovative dialysis devices, advanced care management software, and intelligent sensors for automated patient monitoring. In its over 20-year history, DaVita has overcome many challenges, including regulatory issues, economic fluctuations, and ever-growing competition. Despite these challenges, the company has steadily expanded its position in the industry and established itself as a leading provider of dialysis and related services. DaVita's success is based on a culture of results orientation and a strong commitment to improving patient outcomes. The company understands that each patient has unique needs and that the treatment of kidney disease requires a lifelong commitment. Therefore, DaVita emphasizes individual care and collaboration with patients and their families to ensure optimal care. Overall, DaVita is an innovative company specializing in the provision of dialysis treatments and related services. The company has overcome many challenges in its history and established itself as a leading provider of dialysis and related services. DaVita is committed to improving the quality of life for dialysis patients worldwide and continuously optimizing the treatment of kidney disease.

DaVita SWOT Analysis

Strengths

1. Industry Leadership: DaVita Inc is one of the leading providers of kidney dialysis services in the healthcare industry.

2. Extensive Network: The company operates a vast network of dialysis centers across the United States and internationally.

3. High-Quality Care: DaVita is known for providing exceptional patient care and achieving positive patient outcomes.

Weaknesses

1. Legal and Regulatory Risks: The healthcare industry is subject to strict regulations, which may pose challenges to DaVita's operations.

2. Dependence on Medicare and Medicaid: A significant portion of DaVita's revenue comes from government-funded healthcare programs, making it vulnerable to changes in reimbursement policies.

3. Vulnerability to Litigation: DaVita has faced legal issues in the past, which can impact its reputation and financial performance.

Opportunities

1. Growing Demand for Dialysis Services: The increasing prevalence of chronic kidney disease presents an opportunity for DaVita to expand its customer base.

2. International Expansion: DaVita can explore new markets and expand its presence in countries with a significant need for dialysis services.

3. Technological Advancements: Embracing technological innovations in healthcare can enhance DaVita's operations and improve patient care.

Threats

1. Competitive Landscape: Other major players in the dialysis services industry pose a threat to DaVita's market share and profitability.

2. Pricing Pressure: Pricing pressures from insurance providers and government payers can impact DaVita's financial performance.

3. Economic Downturn: During economic downturns, individuals may delay or forgo non-essential medical treatments, which could affect DaVita's revenue.

DaVita Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

DaVita Employees
Details
Date
DaVita Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

DaVita Segments

DaVita Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

U S Dialysis
U.S. dialysis
Other - Ancillary services
Details
Date
U S Dialysis
U.S. dialysis
Dialysis And Related Lab Services
Guarantor Subsidiaries
Other - Ancillary services
Non-Guarantor Subsidiaries
DaVita Inc
Other Ancillary Services And Strategic Initiatives
Consolidating Adjustments
Jan 1, 2010
0.00 USD
0.00 USD
6.07 B USD
5.20 B USD
0.00 USD
1.29 B USD
431.78 M USD
374.50 M USD
-477.44 M USD
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
957.90 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
10.51 B USD
0.00 USD
0.00 USD
1.04 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
10.58 B USD
0.00 USD
0.00 USD
1.04 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
10.51 B USD
0.00 USD
0.00 USD
1.10 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
10.85 B USD
0.00 USD
0.00 USD
1.29 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
11.73 B USD
0.00 USD
0.00 USD
0.00 USD
1.91 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

DaVita Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • Max

U S Dialysis And Related Lab Services
Details
Date
U S Dialysis And Related Lab Services
Jan 1, 2010
0.00 USD
Jan 1, 2018
10.24 B USD
Jan 1, 2019
10.43 B USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2025
0.00 USD

DaVita Revenue by Segment (3/3)

  • 3 Years

  • 5 Years

  • Max

Other ancillary services and strategic initiatives
Details
Date
Other ancillary services and strategic initiatives
Jan 1, 2010
0.00 USD
Jan 1, 2018
1.16 B USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2025
0.00 USD

DaVita Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

DaVita historical P/E ratio, EBIT multiple, and P/S ratio

DaVita annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

DaVita shares outstanding

The number of shares of DaVita was 88.1 M in 2025. This indicates how many shares DaVita is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
104.84 M Stocks
Jan 1, 2022
91.91 M Stocks
Jan 1, 2023
92.78 M Stocks
Jan 1, 2024
85.80 M Stocks
Jan 1, 2025
88.10 M Stocks
Jan 1, 2026 (e)
88.10 M Stocks
Jan 1, 2027 (e)
88.10 M Stocks
Jan 1, 2028 (e)
88.10 M Stocks

DaVita stock splits

In DaVita's history, there have been no stock splits.

Current DaVita forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
5.88 % (1)
Hold
58.82 % (10)
Sell
35.29 % (6)
12M Price Target
135.66
Last Price
180.67
Currency
USD
12M Return Potential
-24.91 %
LTM Return
0 %

DaVita Analyst Rating Actions

DateFirmActionRatingReliability
7/14/2026
Truist Securities
Truist Securities
MaintainedHold
7/10/2026
UBS
UBS
MaintainedBuy51
7/9/2026
Barclays
Barclays
MaintainedEqual Weight33
5/11/2026
TD Cowen
TD Cowen
MaintainedHold60
5/8/2026
Truist Securities
Truist Securities
MaintainedHold
5/8/2026
Barclays
Barclays
MaintainedEqual Weight33
5/7/2026
UBS
UBS
MaintainedBuy51
5/6/2026
Deutsche Bank
Deutsche Bank
UpgradeHoldBuy
2/4/2026
UBS
UBS
MaintainedBuy51
2/3/2026
Barclays
Barclays
MaintainedEqual Weight33

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

DaVita Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/20263.92USD-3.53 BUSD-2026 Q2
4/30/20262.34USD-3.39 BUSD-2026 Q1
2/2/20263.19USD-3.53 BUSD-2025 Q4
5/6/20241.68USD-3.01 BUSD-2024 Q1
2/20/20241.58USD-3.04 BUSD-2023 Q4
7/31/20231.62USD-2.97 BUSD-2023 Q2
5/3/20231.22USD-2.87 BUSD-2023 Q1
2/8/20231.14USD-2.98 BUSD-2022 Q4
10/28/20221.78USD-3.02 BUSD-2022 Q3
8/1/20222.11USD-2.98 BUSD-2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the DaVita stock

79/100
82
Environment
65
Social
89
Governance
E

Environment

20
Scope 1 - Direct Emissions59,569
Scope 2 - Indirect emissions from purchased energy206,214
Scope 3 - Indirect emissions within the value chain705,383
Total CO₂ emissions265,783
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees78
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

DaVita shareholder structure

% Name
39.66605%
BERKSHIRE HATHAWAY INC
BERKSHIRE HATHAWAY INC
3.64598%
BLACKROCK, INC.
BLACKROCK, INC.
2.87306%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
2.19548%
MORGAN STANLEY
MORGAN STANLEY
1.94979%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
1.93435%
INVESCO LTD.
INVESCO LTD.
...

DaVita Beneficial Ownership Filings (SEC 13D/G)

Free Float
98.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
45.00%
Warren E. Buffett
Warren E. Buffett
SEC ↗
45.00%
Berkshire Hathaway Inc.
Berkshire Hathaway Inc.
SEC ↗
42.20%
TPG Group Holdings (SBS) Advisors, Inc.
TPG Group Holdings (SBS) Advisors, Inc.
SEC ↗
33.40%
Emerson Electric Co.
Emerson Electric Co.
SEC ↗
27.77%
Counsel Portfolio Services Inc.
Counsel Portfolio Services Inc.
SEC ↗
23.00%
National Indemnity Company
National Indemnity Company
SEC ↗
23.00%
Government Employees Insurance Company
Government Employees Insurance Company
SEC ↗
23.00%
GEICO Corporation
GEICO Corporation
SEC ↗
13.20%
Berkshire Hathaway Consolidated Pension Plan Master Trust
Berkshire Hathaway Consolidated Pension Plan Master Trust
SEC ↗
9.80%
Cheshire MD Holdings, LLC
Cheshire MD Holdings, LLC
SEC ↗

DaVita Executives and Management Board

15 members · avg. age 59 · 33 % women

JR

Mr. Javier Rodriguez (54)

Chief Executive Officer, Director · since 2000

21.81 M USD

Management

JA

Mr. Joel Ackerman (60)

Chief Financial Officer, Treasurer

6.35 M USD
DM

Mr. David Maughan (48)

Chief Operating Officer - Davita Kidney Care

4.93 M USD
KW

Ms. Kathleen Waters (57)

Chief Legal and Public Affairs Officer

4.65 M USD
JH

Mr. James Hearty (56)

Chief Compliance Officer

2.34 M USD
CB

Mr. Christopher Berry (50)

Chief Accounting Officer

NE

Mr. Nic Eliason

IR Contact Officer · since 2022

Board of Directors

PA

Ms. Pamela Arway (71)

Independent Chair of the Board

499,708.00 USD
BD

Ms. Barbara Desoer (72)

Independent Director

384,708.00 USD
GM

Dr. Gregory Moore (60)

Independent Director

377,208.00 USD
PY

Ms. Phyllis Yale (67)

Independent Director

374,708.00 USD
JH

Mr. Jason Hollar (52)

Independent Director

372,208.00 USD
AS

Mr. Adam Schechter (60)

Independent Director

334,708.00 USD

DaVita Supply Chain

DaVita Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
8 companies
#Nameβ 1YTrend
1
Berkshire Hathaway B
Supplier·Customer·US
0.83
0.93
0.42
0.25
-0.25
0.57
2
Renalytix
Supplier·Customer·Health Care Technology·GB
0.90
0.87
0.56
0.03
0.52
0.43
#Nameβ 1YTrend
1
-0.43
0.80
0.36
0.22
-0.48
2
Rockwell Medical, Inc.
Supplier·Health Care Equipment & Supplies·US
0.92
0.92
0.84
0.59
0.65
-0.47
3
GEE Group, Inc.
Supplier·Professional Services·US
-0.14
0.51
-0.26
0.20
-0.01
-0.44
4
Amgen Inc.
Supplier·Biotechnology·US
-0.60
-0.86
0.20
0.20
0.24
-0.16
0.20
5
Fresenius
Supplier·Customer·Health Care Providers & Services·DE
0.84
0.71
0.06
0.15
0.70
0.29
0.62

Frequently asked questions about DaVita

The main competitors of DaVita Inc in the market include companies like Fresenius Medical Care Holdings, Inc. and American Renal Associates Holdings, Inc.

DaVita Inc is a leading provider of kidney care services in the United States, offering dialysis treatments and related healthcare services. The company operates a network of outpatient dialysis centers and provides specialized medical care to patients suffering from chronic kidney failure. DaVita's business model revolves around delivering high-quality care with a patient-centric focus. By leveraging their extensive network, technological advancements, and skilled healthcare professionals, DaVita aims to improve patients' quality of life and outcomes. With a strong emphasis on innovation, collaboration, and education, DaVita Inc strives to optimize the overall healthcare experience for individuals with kidney-related conditions.

DaVita Inc is primarily active in the healthcare industry.

DaVita Inc is a leading healthcare provider that specializes in kidney care services. Established in 1999, the company has a strong history of delivering high-quality care to patients across the United States and internationally. DaVita is renowned for its innovative approaches to dialysis treatment and comprehensive disease management. The company operates a vast network of outpatient dialysis centers, partnering with physicians in providing integrated care to individuals with chronic kidney disease. With a commitment to improving patients' quality of life, DaVita remains dedicated to the compassionate delivery of kidney care services. DaVita Inc has continually expanded its footprint and leadership in the industry, making it a trusted name in renal care.

DaVita Inc. has achieved several significant milestones throughout its history. The company has expanded its presence globally, becoming one of the largest providers of kidney care services worldwide. DaVita has consistently demonstrated strong financial performance and steady growth, positioning itself as a leader in the industry. It has also received numerous accolades, including being recognized as one of Fortune's World's Most Admired Companies. DaVita Inc. continues to innovate in the field of healthcare, focusing on delivering high-quality patient care and improving outcomes.

DaVita Inc is primarily present in the United States.

DaVita Inc represents a set of core values and a strong corporate philosophy. The company focuses on delivering quality patient care, guided by their motto: "One for All and All for One." DaVita strives to provide exceptional healthcare services with integrity, teamwork, and continuous improvement. Their commitment to clinical excellence and compassion is evident in their Village concept, where employees are called "teammates" and patients are part of the DaVita community. DaVita promotes a culture of caring, innovation, and accountability, ensuring the highest standards of care for their patients.

Analysts currently set an average price target of 141.80 USD for the DaVita stock (median: 135.66 USD), implying -21.5 % versus the latest price. The consensus is based on 17 analyst ratings.

17 analysts currently rate the DaVita stock: 1 recommend buying, 10 holding and 6 selling. For 2026, analysts expect DaVita to generate revenue of 14.09 B USD and earnings per share of 12.82 USD.

Converted at the current exchange rate, the DaVita share trades at 156.40 EUR (180.67 USD).

The DaVita share (DVA) is listed on 7 stock exchanges, including: NYSE (DVA), Frankfurt (TRL.F), München (TRL.MU), Düsseldorf (TRL.DU), London (0I7E.L), London (0I7E.L), SIX (Zürich) (TRL.SW).

The business model of DaVita Inc is focused on the healthcare and medical services sector. The company's main focus is on treating patients with chronic kidney diseases. DaVita has developed a comprehensive integrated healthcare solution that includes multiple services. These include renal replacement therapy, care, education, and medical treatment. In recent years, the company has also added expanded services such as nutritional counseling, mental health, and rehabilitation to its portfolio. To provide the necessary medical care and healthcare services, DaVita operates around 2,700 dialysis centers with over 200,000 facilities worldwide. The company also employs over 70,000 staff, including physicians, nursing staff, therapists, and administrative personnel. DaVita offers a wide range of products and services, including hemodialysis, peritoneal dialysis, and home patient equipment. The company also offers various programs to improve patient care quality and increase patient engagement. These programs include global quality and safety initiatives, patient surveys, and electronic medical records. DaVita has also established its own health insurance called DaVita Health Plan, which offers a wide range of health plans in the United States. The company also operates a comprehensive marketing program to raise awareness of its services among patients and physicians. To drive growth in different markets, DaVita seeks to offer the best possible healthcare services through strategic acquisitions and joint ventures. In recent years, the company has announced several acquisitions and partnerships to expand its geographic reach and service offerings. In recent years, the company has been following a trend towards digital innovations. DaVita has transitioned its originally paper-based processes to digital platforms to improve care quality, patient experience, and efficiency. The company also utilizes the latest technologies to offer innovative and personalized services to its patients and improve patient experiences. In summary, DaVita Inc is a leading company in the field of kidney diseases and offers a wide range of healthcare services and products. The company has a strong presence in the United States and operates in various geographical regions worldwide. DaVita has evolved its services over the years and developed an extensive portfolio of products and services, including health insurance, digital platforms, and innovative therapies.

The expected revenue of DaVita is 14.09 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of DaVita is 1.13 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of DaVita is currently 14.10. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DaVita stock.

The price-to-sales ratio (P/S) of DaVita is currently 1.13. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DaVita stock.

The Eulerpool Quality Score for DaVita is 6/10.

The ISIN of DaVita is US23918K1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of DaVita is 897914. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of DaVita is DVA. The ticker symbol is used to trade DaVita shares on the stock exchange.

DaVita paid dividends every year for the past 0 years.

DaVita is assigned to the 'Health' sector.

The dividends of DaVita are distributed in USD.

All fundamentals and in-depth analysis of DaVita

Our stock analysis for DaVita stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DaVita. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.